Key Challenges in Oncology and Bioinformatics

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...

3 months ago
Oncology,R&D,Bioprocess,AI & ML,Biology,News

Key Challenges in Oncology and Bioinformatics

This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...

3 months ago

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

8 months ago
Oncology,R&D,Bioinformatics,Biology,News

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

8 months ago

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

9 months ago
Oncology,Bioprocess,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

9 months ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

9 months ago
Oncology,R&D,Biology,News

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

9 months ago

Weekly News Round-up – 17/1/20

The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...

9 months ago
Oncology,Weekly Roundups,Biology

Weekly News Round-up – 17/1/20

The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...

9 months ago

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

10 months ago
Oncology,R&D,Biology,News

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

10 months ago

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

1 year ago
Oncology,Biology,News

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

1 year ago